识别嗅觉表型以区分COVID-19嗅觉功能障碍与鼻窦炎性疾病
本研究对鼻窦炎性疾病、COVID-19感染后嗅觉功能障碍≥4周、阿尔茨海默病和健康对照四组成人进行新型嗅觉测试,将气味评分归一化后对COVID-19和鼻窦炎组进行凝聚层次聚类分析,结果发现聚类检测COVID-19的敏感度为81%、特异度为63%,支持存在可区分COVID-19嗅觉功能障碍与鼻窦炎性疾病的嗅觉表型。
要点
- 新型嗅觉测试结合层次聚类可识别区分COVID-19与鼻窦炎性疾病的嗅觉表型。
- 聚类检测COVID-19的敏感度为81%、特异度为63%。
- 嗅觉表型有望用于嗅觉功能障碍的评估与治疗。
核心结论
- 结果支持存在嗅觉表型,可能区分COVID-19嗅觉功能障碍与鼻窦炎性疾病。
- 这些表型可能越来越多地用于嗅觉功能障碍患者的评估和治疗。
研究设计与样本
- 成人患者按健康状况分为四组:鼻窦炎性疾病(慢性鼻窦炎或过敏性鼻炎)、COVID-19感染康复后自报嗅觉功能障碍≥4周、阿尔茨海默病和健康对照,接受新型嗅觉测试。
- 将每个气味的评分相对于其最差和最好评分归一化至0到1,对COVID-19和鼻窦炎组归一化数据进行凝聚层次聚类分析。
主要发现
- 倒数第二次合并产生的聚类检测COVID-19患者的敏感度为81%、特异度为63%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to identify specific olfactory phenotypes-patterns of olfactory performance-across distinct cohorts with or without olfactory dysfunction (OD). Adult patients underwent testing via a novel olfactory testing methodology in 1 of 4 groups based on health status: sinonasal inflammatory condition (chronic rhinosinusitis or allergic rhinitis), ≥4 weeks of self-reported OD after resolved COVID-19 infection, Alzheimer's disease, and healthy control. Participants' scores for each scent were normalized on a scale of 0 to 1 relative to their worst and best scores. Agglomerative hierarchal cluster analysis was performed on normalized data for the COVID-19 and sinonasal cohorts. Resulting clusters from the penultimate merger revealed a sensitivity of 81% and specificity of 63% for the detection of patients with COVID-19. These results support that there are olfactory phenotypes that may discriminate COVID-19 OD from sinonasal inflammatory disease. These phenotypes will likely become increasingly leveraged in the workup and treatment of patients with OD.
引用
- Somani SN, Farrokhian N, Macke J, et al. Identifying Olfactory Phenotypes to Differentiate Between COVID-19 Olfactory Dysfunction and Sinonasal Inflammatory Disease. Otolaryngol Head Neck Surg. 2022. PMID: 35290133. doi:10.1177/01945998221085500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。